Analysis of fibrin formation and proteolysis during intravenous administration of ancrod

Author:

Dempfle Carl-Erik1,Argiriou Sotiria1,Kucher Klaus1,Müller-Peltzer H.1,Rübsamen Klaus1,Heene Dieter L.1

Affiliation:

1. From the University of Heidelberg, Mannheim University Hospital, First Department of Medicine, Theodor Kutzer Ufer, D-68167 Mannheim, Germany; Knoll AG, D-67008 Ludwigshafen, Germany.

Abstract

Abstract Ancrod is a purified fraction of venom from the Malayan pit viper, Calloselasma rhodostoma, currently under investigation for treatment of acute ischemic stroke. Treatment with ancrod leads to fibrinogen depletion. The present study investigated the mechanisms leading to the reduction of plasma fibrinogen concentration. Twelve healthy volunteers received an intravenous infusion of 0.17 U/kg body weight of ancrod for 6 hours. Blood samples were drawn and analyzed before and at various time points until 72 hours after start of infusion. Ancrod releases fibrinopeptide A from fibrinogen, leading to the formation of desAA-fibrin monomer. In addition, a considerable proportion of desA-profibrin is formed. Production of desA-profibrin is highest at low concentrations of ancrod, whereas desA-profibrin is rapidly converted to desAA-fibrin at higher concentrations of ancrod. Both desA-profibrin and desAA-fibrin monomers form fibrin complexes. A certain proportion of complexes carries exposed fibrin polymerization sites EA, indicating that the terminal component of the protofibril is a desAA-fibrin monomer unit. Soluble fibrin complexes potentiate tissue-type plasminogen activator-induced plasminogen activation. Significant amounts of plasmin are formed when soluble fibrin in plasma reaches a threshold concentration, leading to the proteolytic degradation of fibrinogen and fibrin. In the present setting, high concentrations of soluble fibrin are detected after 1 hour of ancrod infusion, whereas a rise in fibrinogen and fibrin degradation products, and plasmin-α2–plasmin inhibitor complex levels is first detected after 2 hours of ancrod infusion. Ancrod treatment also results in the appearance of cross-inked fibrin degradation productd-dimer in plasma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference32 articles.

1. Therapeutic defibrination by ancrod (Arvin).;Reid;Folia Haematol Int Mag Klin Morphol Blutforsch.,1971

2. The proteolytic actions of ancrod on human fibrinogen and polypeptide chains.;Edgar;Thromb Res.,1973

3. The action of Arvin on fibrin stabilizing factor (factor XIII).;Barlow;Res Commun Chem Pathol Pharm.,1970

4. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.;Prentice;Br J Haematol.,1993

5. SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusions in man.;Lane;Br J Haematol.,1977

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3